$2.27 Billion is the total value of Ikarian Capital, LLC's 230 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DTIL | Exit | PRECISION BIOSCIENCES INC | $0 | – | -8,812 | -100.0% | -0.00% | – |
| OVID | Exit | OVID THERAPEUTICS INCcall | $0 | – | -16,000 | -100.0% | -0.01% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INC | $0 | – | -2,714 | -100.0% | -0.01% | – |
| MESO | Exit | MESOBLAST LTDput | $0 | – | -7,800 | -100.0% | -0.01% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INCput | $0 | – | -10,000 | -100.0% | -0.01% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INCcall | $0 | – | -10,000 | -100.0% | -0.01% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -2,641 | -100.0% | -0.02% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -29,080 | -100.0% | -0.02% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -5,000 | -100.0% | -0.03% | – |
| CRBP | Exit | CORBUS PHARMACEUTICALS HLDGScall | $0 | – | -220,100 | -100.0% | -0.03% | – |
| ADMA | Exit | ADMA BIOLOGICS INC | $0 | – | -200,000 | -100.0% | -0.04% | – |
| AL | Exit | AIR LEASE CORPput | $0 | – | -17,600 | -100.0% | -0.04% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -18,726 | -100.0% | -0.04% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -50,000 | -100.0% | -0.06% | – |
| AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -177,684 | -100.0% | -0.06% | – |
| IMMU | Exit | IMMUNOMEDICS INCcall | $0 | – | -16,100 | -100.0% | -0.10% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -125,000 | -100.0% | -0.12% | – |
| APTX | Exit | APTINYX INC | $0 | – | -495,490 | -100.0% | -0.12% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS IN | $0 | – | -2,389,891 | -100.0% | -0.19% | – |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -95,430 | -100.0% | -0.20% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -340,318 | -100.0% | -0.20% | – |
| MYOV | Exit | MYOVANT SCIENCES LTDcall | $0 | – | -200,000 | -100.0% | -0.20% | – |
| PAND | Exit | PANDION THERAPEUTICS INC | $0 | – | -260,000 | -100.0% | -0.22% | – |
| LSAC | Exit | LIFESCI ACQUISITION CORP | $0 | – | -241,762 | -100.0% | -0.22% | – |
| EIDX | Exit | EIDOS THERAPEUTICS INC | $0 | – | -63,011 | -100.0% | -0.23% | – |
| ARYBU | Exit | ARYA SCIENCES ACQUISTION COunit 06/09/2027 | $0 | – | -318,206 | -100.0% | -0.25% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INCput | $0 | – | -100,000 | -100.0% | -0.30% | – |
| HST | Exit | HOST HOTELS & RESORTS INCput | $0 | – | -400,000 | -100.0% | -0.31% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS INput | $0 | – | -100,000 | -100.0% | -0.37% | – |
| CCXI | Exit | CHEMOCENTRYX INCcall | $0 | – | -100,000 | -100.0% | -0.40% | – |
| ATRA | Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -426,800 | -100.0% | -0.40% | – |
| RPTX | Exit | REPARE THERAPEUTICS INC | $0 | – | -190,410 | -100.0% | -0.42% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS INcall | $0 | – | -150,000 | -100.0% | -0.47% | – |
| CYTK | Exit | CYTOKINETICS INCput | $0 | – | -320,000 | -100.0% | -0.50% | – |
| INCY | Exit | INCYTE CORPput | $0 | – | -100,000 | -100.0% | -0.65% | – |
| MPW | Exit | MEDICAL PPTYS TRUST INCput | $0 | – | -600,000 | -100.0% | -0.77% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INCput | $0 | – | -326,500 | -100.0% | -0.81% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -117,100 | -100.0% | -0.83% | – |
| INCY | Exit | INCYTE CORPcall | $0 | – | -150,000 | -100.0% | -0.97% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INCcall | $0 | – | -114,900 | -100.0% | -0.99% | – |
| KOD | Exit | KODIAK SCIENCES INCput | $0 | – | -250,000 | -100.0% | -1.07% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB COcall | $0 | – | -300,000 | -100.0% | -1.31% | – |
| IGMS | Exit | IGM BIOSCIENCES INCcall | $0 | – | -250,000 | -100.0% | -1.34% | – |
| BCLI | Exit | BRAINSTORM CELL THERAPEUTICSput | $0 | – | -1,170,100 | -100.0% | -1.43% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INCput | $0 | – | -549,000 | -100.0% | -6.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.